Resmed Stock Rises After Goldman Sachs Inclusion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Source: Yahoo Finance
Resmed's stock price increased by 3.58%, reaching a 20-day high, following its addition to Goldman Sachs' APAC Conviction List, which has renewed optimism about the company's growth potential. The inclusion reflects confidence in Resmed's ability to expand its patient base and maintain momentum ahead of its fiscal Q4 2026 results. Despite this positive news, the stock remains down 14.5% year-to-date, indicating ongoing investor caution regarding future profitability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RMD
Wall Street analysts forecast RMD stock price to rise
11 Analyst Rating
6 Buy
5 Hold
0 Sell
Moderate Buy
Current: 218.400
Low
260.00
Averages
294.00
High
345.00
Current: 218.400
Low
260.00
Averages
294.00
High
345.00
About RMD
ResMed Inc. is a holding company. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. It also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Resmed Sells MatrixCare Business to Frazier Healthcare Partners
- Strategic Restructuring: Resmed announced the sale of its MatrixCare business to Frazier Healthcare Partners, aiming to focus on high-growth opportunities in sleep health and home healthcare, thereby optimizing resource allocation and enhancing long-term value creation.
- Market Impact: MatrixCare provides software solutions to over 15,000 providers across skilled nursing, senior living, and home health sectors, and this transaction is expected to further strengthen its influence in the long-term care market.
- Investment Commitment: Frazier Healthcare Partners plans to invest aggressively in product innovation for MatrixCare, aiming to improve service quality in the post-acute care sector, reflecting confidence in the future development of this market.
- Transaction Expectations: The deal is expected to close in the first quarter of Resmed's fiscal year 2027, subject to regulatory approvals and customary closing conditions, with MatrixCare continuing to operate as part of Resmed until the transaction is finalized to ensure uninterrupted customer service.
See More
Frazier Healthcare Partners to Acquire MatrixCare from Resmed
- Acquisition Agreement: Frazier Healthcare Partners announced a definitive agreement to acquire MatrixCare from Resmed, which provides cloud-based EHR software tailored for out-of-hospital care settings, with the transaction expected to close in Q3 2026, marking a strategic move into post-acute care technology.
- Market Leadership: MatrixCare has established itself as a leading platform serving skilled nursing, senior living, home health, and hospice sectors, and Frazier's years of evaluation indicate that this acquisition will bolster its position in the growing post-acute care technology market.
- Strategic Alignment: Resmed's CEO Mick Farrell stated that this divestiture aligns with the company's 2030 strategy focused on portfolio management, demonstrating a clear direction for future growth while ensuring excellent stewardship for MatrixCare's team and solutions.
- Industry Outlook: This acquisition not only provides Frazier with an opportunity to enter the rapidly growing post-acute care market but also has the potential to enhance its competitiveness in healthcare by integrating MatrixCare's technology and resources, thereby driving further business expansion.
See More
Resmed Sells MatrixCare to Focus on Core Healthcare
- Business Sale: Resmed has agreed to sell its MatrixCare business to private equity firm Frazier Healthcare Partners, aiming to sharpen its focus on sleep, breathing, and home healthcare, with the transaction expected to close in the first quarter of fiscal 2027.
- Market Coverage: MatrixCare provides software to over 15,000 providers across skilled nursing, senior living, home health, and hospice care, and selling this business will allow Resmed to concentrate resources on more strategically significant core operations.
- Financial Impact: This transaction is expected to help Resmed optimize its financial structure, although specific financial terms have not been disclosed, it is anticipated to enhance the company's cash flow and investment capacity to support future innovation and growth.
- Industry Dynamics: Resmed's strategic adjustment reflects a keen response to market changes within the medical device industry, particularly in light of competitors like Philips re-entering the market and potential threats from GLP-1 drugs, thereby strengthening its competitive position.
See More
ResMed Stock Rises After Goldman Sachs Inclusion
- Goldman Sachs Impact: ResMed's stock rose 3.7% after being added to Goldman Sachs' APAC Conviction List, reflecting renewed optimism about the company's patient base growth and overall momentum, particularly ahead of its fiscal Q4 2026 results.
- Positive Market Reaction: Trading at $209.27, ResMed shares are up 4.1% from the previous close, indicating that the market considers this news significant, despite potential headwinds facing the healthcare sector.
- Volatility Analysis: With only two moves greater than 5% in the past year, ResMed's stock indicates that today's movement is meaningful, although it does not fundamentally alter the market's perception of the business, suggesting cautious investor sentiment.
- Long-term Performance Review: ResMed is down 14.5% year-to-date and is trading 28.8% below its 52-week high of $293.73, highlighting investor concerns about future profitability, especially with competitors potentially re-entering the market.
See More
ResMed Announces Q3 2026 Financial Results and Upcoming Webcast
- Significant Revenue Growth: ResMed reported a net revenue of $1.43 billion for Q3 2026, reflecting a 10.8% increase driven primarily by $1.26 billion in sales from the Sleep and Breathing segment, indicating strong performance in the medical device market.
- Profit Increase: The net income for Q3 rose by 9.2% to $0.39 billion compared to $0.36 billion last year, showcasing the company's success in cost control and responding to market demand.
- Earnings Per Share Rise: The earnings per share for Q3 reached $2.74, up 10.4%, while non-GAAP net income increased by 19.7% to $0.41 billion, demonstrating ongoing improvements in profitability.
- Strong Cash Reserves: As of March 31, 2026, ResMed reported cash and cash equivalents of $1.66 billion, providing robust financial support for future investments and operations.
See More
ResMed Stock Price Potential Analysis
- Stock Price Trend: ResMed (RMD) has seen a 6.6% increase in its stock price over the past four weeks, closing at $194.88, indicating optimistic market sentiment that may attract more investor interest.
- Analyst Price Targets: The average price target from Wall Street analysts stands at $249.86, suggesting a potential upside of 28.2%, although the lowest target of $180.00 reflects some divergence in market views on the stock.
- Improved Earnings Outlook: Analysts are optimistic about ResMed's earnings prospects, with expectations for upward revisions in earnings estimates, and while the current year's Zacks Consensus Estimate remains unchanged, it indicates growing confidence in the company's future performance.
- Cautious Investor Sentiment: Although price targets may not be reliable, the strong consensus among analysts regarding earnings expectations reflects heightened optimism, suggesting that investors should remain cautious and avoid making decisions based solely on price targets.
See More
Resmed Sells MatrixCare Business to Frazier Healthcare Partners
- Strategic Restructuring: Resmed announced the sale of its MatrixCare business to Frazier Healthcare Partners, aiming to focus on high-growth opportunities in sleep health and home healthcare, thereby optimizing resource allocation and enhancing long-term value creation.
- Market Impact: MatrixCare provides software solutions to over 15,000 providers across skilled nursing, senior living, and home health sectors, and this transaction is expected to further strengthen its influence in the long-term care market.
- Investment Commitment: Frazier Healthcare Partners plans to invest aggressively in product innovation for MatrixCare, aiming to improve service quality in the post-acute care sector, reflecting confidence in the future development of this market.
- Transaction Expectations: The deal is expected to close in the first quarter of Resmed's fiscal year 2027, subject to regulatory approvals and customary closing conditions, with MatrixCare continuing to operate as part of Resmed until the transaction is finalized to ensure uninterrupted customer service.
See More
Frazier Healthcare Partners to Acquire MatrixCare from Resmed
- Acquisition Agreement: Frazier Healthcare Partners announced a definitive agreement to acquire MatrixCare from Resmed, which provides cloud-based EHR software tailored for out-of-hospital care settings, with the transaction expected to close in Q3 2026, marking a strategic move into post-acute care technology.
- Market Leadership: MatrixCare has established itself as a leading platform serving skilled nursing, senior living, home health, and hospice sectors, and Frazier's years of evaluation indicate that this acquisition will bolster its position in the growing post-acute care technology market.
- Strategic Alignment: Resmed's CEO Mick Farrell stated that this divestiture aligns with the company's 2030 strategy focused on portfolio management, demonstrating a clear direction for future growth while ensuring excellent stewardship for MatrixCare's team and solutions.
- Industry Outlook: This acquisition not only provides Frazier with an opportunity to enter the rapidly growing post-acute care market but also has the potential to enhance its competitiveness in healthcare by integrating MatrixCare's technology and resources, thereby driving further business expansion.
See More
Resmed Sells MatrixCare to Focus on Core Healthcare
- Business Sale: Resmed has agreed to sell its MatrixCare business to private equity firm Frazier Healthcare Partners, aiming to sharpen its focus on sleep, breathing, and home healthcare, with the transaction expected to close in the first quarter of fiscal 2027.
- Market Coverage: MatrixCare provides software to over 15,000 providers across skilled nursing, senior living, home health, and hospice care, and selling this business will allow Resmed to concentrate resources on more strategically significant core operations.
- Financial Impact: This transaction is expected to help Resmed optimize its financial structure, although specific financial terms have not been disclosed, it is anticipated to enhance the company's cash flow and investment capacity to support future innovation and growth.
- Industry Dynamics: Resmed's strategic adjustment reflects a keen response to market changes within the medical device industry, particularly in light of competitors like Philips re-entering the market and potential threats from GLP-1 drugs, thereby strengthening its competitive position.
See More
ResMed Stock Rises After Goldman Sachs Inclusion
- Goldman Sachs Impact: ResMed's stock rose 3.7% after being added to Goldman Sachs' APAC Conviction List, reflecting renewed optimism about the company's patient base growth and overall momentum, particularly ahead of its fiscal Q4 2026 results.
- Positive Market Reaction: Trading at $209.27, ResMed shares are up 4.1% from the previous close, indicating that the market considers this news significant, despite potential headwinds facing the healthcare sector.
- Volatility Analysis: With only two moves greater than 5% in the past year, ResMed's stock indicates that today's movement is meaningful, although it does not fundamentally alter the market's perception of the business, suggesting cautious investor sentiment.
- Long-term Performance Review: ResMed is down 14.5% year-to-date and is trading 28.8% below its 52-week high of $293.73, highlighting investor concerns about future profitability, especially with competitors potentially re-entering the market.
See More
ResMed Announces Q3 2026 Financial Results and Upcoming Webcast
- Significant Revenue Growth: ResMed reported a net revenue of $1.43 billion for Q3 2026, reflecting a 10.8% increase driven primarily by $1.26 billion in sales from the Sleep and Breathing segment, indicating strong performance in the medical device market.
- Profit Increase: The net income for Q3 rose by 9.2% to $0.39 billion compared to $0.36 billion last year, showcasing the company's success in cost control and responding to market demand.
- Earnings Per Share Rise: The earnings per share for Q3 reached $2.74, up 10.4%, while non-GAAP net income increased by 19.7% to $0.41 billion, demonstrating ongoing improvements in profitability.
- Strong Cash Reserves: As of March 31, 2026, ResMed reported cash and cash equivalents of $1.66 billion, providing robust financial support for future investments and operations.
See More
ResMed Stock Price Potential Analysis
- Stock Price Trend: ResMed (RMD) has seen a 6.6% increase in its stock price over the past four weeks, closing at $194.88, indicating optimistic market sentiment that may attract more investor interest.
- Analyst Price Targets: The average price target from Wall Street analysts stands at $249.86, suggesting a potential upside of 28.2%, although the lowest target of $180.00 reflects some divergence in market views on the stock.
- Improved Earnings Outlook: Analysts are optimistic about ResMed's earnings prospects, with expectations for upward revisions in earnings estimates, and while the current year's Zacks Consensus Estimate remains unchanged, it indicates growing confidence in the company's future performance.
- Cautious Investor Sentiment: Although price targets may not be reliable, the strong consensus among analysts regarding earnings expectations reflects heightened optimism, suggesting that investors should remain cautious and avoid making decisions based solely on price targets.
See More
